Applicant: Tatsuhiko Kodama et al. Attorney's Docket No.: 14875-0152US1 / C1-A0306P-US

Serial No.: 10/550,987 Filed: May 25, 2006

Page : 2 of 6

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

## **Listing of Claims**:

1-27. (Canceled)

- 28. (Currently amended) A method for inhibiting peptide transporter activity, the method comprising contacting
- (a) an isolated antibody or antigen-binding fragment thereof that (i) binds to a <u>PepT1 or PepT2</u> peptide transporter and (ii) inhibits peptide uptake into a cell expressing the peptide transporter, with
- (b) a cell expressing the peptide transporter, wherein the antibody is a monoclonal or genetically engineered recombinant antibody, and wherein the cell is *in vivo*.

29-31. (Cancelled)

- 32. (Previously presented) The method of claim 28, wherein the antibody is monoclonal.
  - 33. (Cancelled)
- 34. (Previously presented) The method of claim 28, wherein the antibody is human or humanized.
- 35. (Currently amended) A method for suppressing cell growth, the method comprising contacting (a) an isolated antibody or antigen-binding fragment thereof that (i) binds

Applicant: Tatsuhiko Kodama et al. Attorney's Docket No.: 14875-0152US1 / C1-A0306P-US

Serial No.: 10/550,987 Filed: May 25, 2006

Page : 3 of 6

to a <u>PepT1 or PepT2</u> peptide transporter and (ii) inhibits peptide uptake into a cell expressing the peptide transporter, with

- (b) a cell expressing the peptide transporter, wherein the antibody is a monoclonal or genetically engineered recombinant antibody, the cell is *in vivo*, and growth of the cell is suppressed.
- 36. (Previously presented) The method of claim 35, wherein the antibody is monoclonal.
  - 37. (Cancelled)
- 38. (Previously presented) The method of claim 35, wherein the antibody is human or humanized.
  - 39-41. (Cancelled)
  - 42. (Previously presented) The method of claim 35, wherein the cell is a cancer cell.
- 43. (Previously presented) The method of claim 35, wherein the cell is a pancreatic cancer cell.
- 44. (Previously presented) The method of claim 28, wherein the cell is in a patient and the antibody or fragment thereof is administered to the patient.
- 45. (Previously presented) The method of claim 35, wherein the cell is in a patient and the antibody or fragment thereof is administered to the patient.